Endometriosis Market To Reach USD 2.42 Billion By 2026 | Reports And Data

New York, March 05, 2020 (GLOBE NEWSWIRE) -- The Global endometriosis market is forecast to reach USD 2.42 Billion by 2026, according to a new report by Reports and Data. Endometriosis is the resultant of the growth of endometrial tissue on bowel, ovaries, and tissues lining the pelvis. The hormonal changes associated with the menstrual cycle impacts the misplaced endometrial tissue that results in the area to become inflamed that causes pain. It implies that the tissue will thicken, grow, and break down. With time, the tissue that broken down has nowhere to go and becomes trapped in pelvis.

The market is projected to witness considerable growth during the forecast period. One of the mentionable factors in this regards being, the increasing occurrence rate of the condition. It has turned out to be a common gynecological condition, affecting approximately 10% of women. Treatment for the disease is dependent on the severity of the disease, symptoms, and if the care user wishes to have children. The condition is treatable with surgery, medication, or both. Medication is usually tried first when pain is the primary problem.

Request free sample of this research report at: https://www.reportsanddata.com/sample-enquiry-form/2553

Medications that are prescribed to treat the condition include pain relievers like nonsteroidal anti-inflammatory drugs (NSAIDs), and hormonal medications, including gonadotropin-releasing hormone agonists and birth control pills, progestin. Hormonal medications help minimize the growth of the endometrial tissue and may prevent the formation of new adhesions. Though it is mentionable that, these drugs are usually not effective in getting rid of endometriosis tissue that is already there. In regards to surgical options, Conservative surgery like Laparoscopy, hysterectomy are some of the available options.

In context to region, Europe occupies a prominent market position. The market position held by the region is resultant of the continuous growth of the healthcare sector and rising investment in the industry.   

Further key findings from the report suggest

• The endometriosis market held a market share of USD 1.93 Billion in the year 2018 and forecasted to grow at a rate of 2.8% during the forecast period.
• In regards to Drug Type, the NSAID’s segment generated the highest revenue of USD 0.58 Billion in 2018, with a growth rate of 2.9% during the forecast period. The effectiveness of the medicine in relieving pain caused by the condition, which are nonsteroidal anti-inflammatory drugs that work by discontinuing the release of prostaglandins that is one of the main chemicals resulting in the pain, contributes to the revenue generated by the NSAID’s segment.
• In context to Surgery Type, the Laparoscopy segment yielded the highest revenue of USD 0.87 Billion in 2018, with the fastest growth rate of 3.2% during the forecast period. The effectiveness of this surgery in accurately diagnosing endometriosis and even eliminate it in mild-moderate condition with just a small incision resulted in its increased demand and revenue generated by the    
• In regards to the End-users, the Drugstores segment can be seen to occupy the largest market share of 30.2% in 2018, with the second-highest growth rate of 3.1% during the forecast period. The fact that in most cases of endometriosis, pain in the primary issue, in which medication is the first choice, has resulted in high dependency on drugstores for availing the prescribed medication, which contributes to the market share occupied by this segment.
• In context to region, Asia Pacific is projected to witness the fastest growth rate of 5.5% during the forecast period, which occupied the second-largest market share of 24.3% in 2018. The growth rate experienced by the Asia Pacific region is resultant of continuous growth in healthcare technology and the rising awareness about women’s health.
• Key participants include Johnson & Johnson Services Inc., Bayer AG, Neurocrine Biosciences Inc., Meditrina Pharmaceuticals Inc., AbbVie Inc., Astellas Pharma Inc., AstraZeneca Plc, Evotec AG, Debiopharm Group and Teva Pharmaceutical Industries Ltd.

For the purpose of this report, Reports and Data have segmented the global endometriosis market based on Surgery Type, Drug Type, End-Users, and region:

Surgery Type Outlook (Revenue, USD Billion; 2016-2026)

• Laparoscopy
• Laparotomy
• Pelvic nerves surgery

Drug Type Outlook (Revenue, USD Billion; 2016-2026)

• NSAID’s
• Gonadotropins Releasing Hormone Agonists
• Progestin
• Oral Contraceptive Pills

End-Users Type Outlook (Revenue, USD Billion; 2016-2026)

• Hospital
• Pharmacies
• Drugstores
• E-commerce

To identify the key trends in the industry, click on the link below:   https://www.reportsanddata.com/report-detail/endometriosis-market

Regional Outlook (Revenue, USD Billion; 2016-2026)

• North America
  • U.S
• Europe
  • U.K
  • France
• Asia Pacific
  • China
  • India
  • Japan
• MEA
• Latin America
  • Brazil

Browse more similar reports on Diagnostics category by Reports And Data

Photomedicine Market - https://www.reportsanddata.com/report-detail/photomedicine-market

In-Vitro Diagnostics (IVD) Quality Control Market - https://www.reportsanddata.com/report-detail/in-vitro-diagnostics-ivd-quality-control-market

Point of Care (PoC) Diagnostics Market - https://www.reportsanddata.com/report-detail/point-of-care-poc-diagnostics-market

About Reports and Data

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power, and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.

Contact Us:

John Watson

Head of Business Development

Reports And Data | Web: www.reportsanddata.com

Direct Line: +1-212-710-1370

E-mail: sales@reportsanddata.com